(Q51025072)
Statements
Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy (English)
M Borte
V Cristea
H H Peter
B H Belohradsky
V Wahn
J Neufang-Hüber
O Zenker